Medicofarma Biotech Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
Medicofarma Biotech has a total shareholder equity of PLN8.7M and total debt of PLN1.5M, which brings its debt-to-equity ratio to 17.4%. Its total assets and total liabilities are PLN14.7M and PLN6.0M respectively.
Anahtar bilgiler
17.4%
Borç/özkaynak oranı
zł1.51m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | zł12.65k |
| Eşitlik | zł8.70m |
| Toplam yükümlülükler | zł6.05m |
| Toplam varlıklar | zł14.75m |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: MDB's short term assets (PLN3.1M) do not cover its short term liabilities (PLN3.7M).
Uzun Vadeli Yükümlülükler: MDB's short term assets (PLN3.1M) exceed its long term liabilities (PLN2.4M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: MDB's net debt to equity ratio (17.2%) is considered satisfactory.
Borcun Azaltılması: MDB's debt to equity ratio has increased from 0% to 17.4% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: MDB has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if MDB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.